Morgan Stanley Asia (Singapore) Pte. Ltd. is a prominent financial services provider, specializing in investment banking, securities trading, and wealth management. The firm delivers comprehensive solutions including capital raising, mergers and acquisitions advisory, and research services, catering to a diverse clientele across the Asia-Pacific region.
As per the latest corporate shareholdings filed, Morgan Stanley Asia (Singapore) Pte. publicly holds 11 stocks with a net worth of over Rs. 1,980.8 crore.
Here are stocks backed by Morgan Stanley with Net Profit CAGR up to 70% in three years.
Cyient DLM Ltd
Cyient DLM Ltd is an integrated electronic manufacturing services company and solutions provider. The Company’s geographical segments include Domestic (Within India) and Overseas (Outside India). Its electronic manufacturing services are provided as build-to-print (B2P) and build-to-specification (B2S) services for its clients.
With a market capitalization of Rs 5,028 crore, the shares closed on Friday at Rs 634 per share, increasing around 1.77 percent as compared to the previous closing price.
Morgan Stanley Asia Singapore Pte holds 2,600,527 shares, i.e. equivalent to 3.3 percent of the company as of September 2024.
The company’s consolidated net profit numbers have showcased an increase from Rs 7 crores during Q2FY23 to Rs 16 crores in Q2FY25. The company has a net profit CAGR for 3 years is 31.73 percent.
Nuvama Wealth Management Ltd
Nuvama Wealth Management Limited is an India-based holding company. The Company’s subsidiaries include Nuvama Clearing Services Limited, Nuvama Financial Services Inc., Nuvama Wealth Finance Limited, Nuvama Wealth and Investment Limited, Nuvama Asset Management Limited and others.
With a market capitalization of Rs 23,307 crore, the shares closed on Friday at Rs 6,509.10 pershare, increasing around 0.41 percent as compared to the previous closing price. Morgan Stanley Asia Singapore Pte holds 4,25,716 shares, i.e. equivalent to 1.2 percent of the company as of September 2024.
The company’s consolidated net profit numbers have showcased an increase from Rs 85 crores during Q2FY23 to Rs 257 crores in Q2FY25. The company has a net profit CAGR for 3 years is 44.60 percent.
Strides Pharma Science Ltd
Strides Pharma Science Limited develops and manufactures intellectual property-led specialized pharmaceutical products. The company works in two segments: pharmaceutical and bio-pharmaceutical.
With a market capitalization of Rs 13,876 crore, the shares closed on Friday at Rs 1,509 per share, increasing around 0.39 percent as compared to the previous closing price.
Morgan Stanley Asia Singapore Pte holds 1,240,786 shares, i.e. equivalent to 1.4 percent of the company as of September 2024.
The company’s consolidated net profit numbers have showcased an increase from Rs 19 crores during Q2FY23 to Rs 94 crores in Q2FY25. The company has a net profit CAGR for 3 years is 70 percent.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
